Creso Pharma Limited announced its engagement to expand the commercialization and distribution of anibidiol®, its CBD-based complimentary animal feed product following a successful launch in Switzerland.
The launch of anibidiol® in Switzerland in November 2017, with animal pharmaceutical giant Virbac Switzerland, has generated early revenue for the company as well as very encouraging feedback for the product from customers and veterinarians. Creso are planning to commercialise the anibidiol® range across global markets throughout 2018 and beyond.
Rolf Heeb, Managing Director of Virbac Switzerland said, “We have been assured by the interest from vets that it was the right move and the right time to launch anibidiol®. There has been great interest from both vets and pet owners since its launch.”
This view has been further endorsed by Swiss vet Dr. Fabian Huwiler who added, “anibidiol® is a unique natural, organic and efficient feed supplement improving the quality of life of the pet and the pet owner; we were waiting for such a product”.
The global animal health market is valued at USD$30 billion2 and is projected to continue to grow rapidly. 41 percent of pet owners have considered or tried various alternative therapies including nutritional supplements (29 percent) and herbal remedies (7 percent)3.
“This promising start with anibidiol® in Switzerland sets a very sound foundation for Creso Pharma to progress into the international market arena”, said Creso Pharma Co-Founder and Chief Executive Officer Dr. Miri Halperin Wernli.
Creso is in the process to expand the anibidiol® product range through the development of additional products for companion animals with further launches with Virbac planned in 2018.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.